- Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients
-
Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, Lim ST, Jeon YW, Gwak H
- KMID: 2511779
- J Breast Cancer.
- 2020 Jun;23(3):259-267.
- doi: 10.4048/jbc.2020.23.e34
Purpose: Neoadjuvant chemotherapy (NAC) involving trastuzumab markedly increases pathologic complete response (pCR) rates in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Despite increasing pCR rates, long-term... -
- CITED
-
- Close
- SHARE
-
- Close
